Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 18/20 | 1.00 |
| ▸ | MMP1 | P03956 | 16/20 | 1.00 |
| ▸ | MMP13 | P45452 | 13/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5892680 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP13 | |
| SCHEMBL5892624 | 0.86 | ADAM17 (1.00) | ADAM17MMP1MMP13 | |
| SCHEMBL5892703 | 0.86 | ADAM17 (1.00) | ADAM17MMP1MMP13 | |
| SCHEMBL5892754 | 0.85 | ADAM17 (1.00) | ADAM17MMP1MMP13 | |
| SCHEMBL5892787 | 0.85 | ADAM17 (1.00) | ADAM17MMP1MMP13 | |
| SCHEMBL5892643 | 0.85 | ADAM17 (1.00) | ADAM17MMP1MMP13 | |
| SCHEMBL5892640 | 0.85 | ADAM17 (1.00) | ADAM17MMP1MMP13 | |
| SCHEMBL7110287 | 0.84 | ADAM17 (0.77) | ADAM17MMP1MMP13 | |
| SCHEMBL5892611 | 0.84 | ADAM17 (1.00) | ADAM17MMP1MMP13 | |
| SCHEMBL5892612 | 0.84 | ADAM17 (1.00) | ADAM17MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1081137-A1 | Selective inhibitors of aggrecanase in osteoarthritis treatment | Pfizer Products Inc. (US) | 2001-03-07 | — | — | EP | claimed |
| US-7030242-B2 | Selective inhibition of aggrecanase in osteoarthritis treatment | PFIZER INC (US) | 2006-04-18 | — | — | US | disclosed |
| US-20050227997-A1 | 1-[4-(2-methyl-benzyloxy)-benzenesulfonyl]-4-aminoacetyl-3-methyl-piperazine-2-carboxylic acid hydroxyamide; potent enzyme inhibitor of metalloproteinases, for treating joint disease, prevent cartilage destruction | NOE MARK C | 2005-10-13 | — | — | US | disclosed |
| EP-1081137-A1 | Selective inhibitors of aggrecanase in osteoarthritis treatment | Pfizer Products Inc. (US) | 2001-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227997-A1 | 1-[4-(2-methyl-benzyloxy)-benzenesulfonyl]-4-aminoacetyl-3-methyl-piperazine-2-carboxylic acid hydroxyamide; potent enzyme inhibitor of metalloproteinases, for treating joint disease, prevent cartilage destruction | MMP3, MMP1, MMP13 | ADAM17 18/4885MMP1 2/4885MMP13 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.